Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Reversal of cardiomyopathy demonstrated in phase II trial of Replagal

May 21, 2001

Adenosine Therapeutics obtains license from Penn State with diabetes application

May 18, 2001

Dipeptide Y1 antagonist reduces food intake and body weight gain in rats

May 18, 2001

Structure elucidation reported for highly potent, naturally produced glucose-6-phosphatase inhibitor

May 18, 2001

Zometa shows efficacy in treatment of SREs in several tumor types

May 18, 2001

Neurogen and Pfizer codevelop new NPY Y1 antagonists, describe potential uses

May 17, 2001

Substituted biphenyls act as glucagon receptor antagonists, as reported by Bayer

May 17, 2001

Novo Nordisk presents new compounds for diabetes and related disorders

May 17, 2001

Serono and Alkermes to develop sustained-release formulation of rhFSH

May 17, 2001

BioSante begins phase II trial of testosterone gel for treatment of FSD

May 17, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
New 5-HT2C receptor agonists reported in Hansoh patent
BioWorld Science
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...